通过polymyxin B修饰的脂质体来缓解LPS吸附和炎症,用于动脉样硬化治疗
Huiwen Liu1, Honglan Wang1, Qiyu Li2
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430022, China.
Acta pharmaceutica Sinica. B
|September 18, 2023
概括
这项研究开发了与多素 (PLPs) 结合的PEGylated脂质体,以向动脉样硬化中的脂多糖 (LPS). PLPs有效地减少了炎症和斑块负担,为动脉样硬化提供了一种新的治疗策略.
科学领域:
- 生物医学工程 生物医学工程
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
背景情况:
- 慢性炎症驱动动动脉硬化 (AS) 的进展.
- 循环中的高脂多糖 (LPS) 与AS严重程度相关.
- LPS促进M1巨细胞的两极分化,加剧炎症和AS.
研究的目的:
- 为AS治疗开发一种针对循环中的LPS的新型治疗策略.
- 调查聚素 (PMB) 结合的PEG化脂质体 (PLPs) 在吸附LPS和减轻AS方面的疗效.
- 评估PLPs对巨细胞极化和动脉样硬化斑块发育的影响.
主要方法:
- 用于LPS吸附的PMB结合的PLP的配方.
- 在体外评估LPS吸附,M1巨分化和泡细胞形成.
- 在AS动物模型中对PLP的体内评估,包括血清LPS水平,细胞因子概况,斑块内的巨细胞极化,斑块稳定性和负担.
主要成果:
- 在实验室中,PLP表现出有效的LPS吸附.
- PLPs减少了M1巨细胞的两极分化,并抑制了泡细胞的形成.
- 在体内,PLPs降低了血清LPS和促炎细胞因子.
- PLPs稳定了AS斑块,减少了斑块中的M1巨细胞,减轻了斑块负担,从而抑制了AS的进展.
结论:
- 循环的LPS是AS的一个可行的治疗点.
- 与PMB结合的PLP通过向LPS来代表AS治疗的有希望的替代策略.
- 这种方法提供了一种通过有针对性的炎症减少来管理动脉样硬化的新方法.
相关概念视频
01:19Formation of Lipopolysaccharides
40
Lipopolysaccharides (LPS) are crucial components of the outer membrane of Gram-negative bacteria, serving both structural and functional roles. It contributes to membrane stability and protects bacteria from host immune responses. LPS is composed of three major regions—lipid A, a core oligosaccharide, and an O antigen. The biosynthesis and assembly of LPS involve a highly coordinated set of enzymatic reactions and transport mechanisms. Additionally, LPS is recognized as an endotoxin,...
40
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
696
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
696
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:30Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
01:38Inflammation
53.8K
Overview
53.8K